4 Healthcare Stocks to Buy Now

Core Insights - The healthcare sector is currently undervalued compared to AI stocks, presenting investment opportunities in innovative healthcare companies [1][2] Group 1: Commercial Momentum - Crispr Therapeutics and Vertex Pharmaceuticals have developed Casgevy, the first gene-editing treatment approved for sickle cell disease and beta-thalassemia, with Vertex reporting $30 million in sales for Casgevy in Q2 2025, indicating market traction [3] - By mid-2025, 75 hospitals and clinics were authorized to administer Casgevy, with around 115 patients beginning treatment, suggesting potential growth in patient numbers and sales through 2025 and 2026 [4] - Crispr is also advancing other treatments like CTX112, a cell-based therapy for cancer and immune diseases, with potential positive data expected in late 2025 [5] Group 2: Late-Stage Catalysts - Intellia Therapeutics is progressing two CRISPR gene-editing programs, with a Phase 3 study for hereditary angioedema nearing completion and topline results expected in the first half of 2026 [6] - The company is also conducting a pivotal trial for ATTR amyloidosis, with earlier tests showing a 91% reduction in TTR protein levels in many patients [7] - Success in these programs could position Intellia as a leader in single-dose, in vivo CRISPR therapy, potentially reshaping market valuations for gene-editing companies [8] Group 3: Platform Plays with Pharma Validation - Recursion Pharmaceuticals operates an AI-driven drug discovery platform, generating $19.2 million in revenue primarily from collaborations with major pharmaceutical companies [9] - Upcoming clinical trial updates in 2025 could enhance market perception of its AI-discovered drugs, unlocking significant upside for the stock [10] Group 4: Obesity Treatment Development - Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist for obesity, showing up to 14.7% average weight loss in mid-stage studies and currently undergoing large late-stage trials [11] - Despite a decline in stock value due to gastrointestinal side effects from an oral formulation, a slower titration schedule may improve tolerability, keeping both injectable and oral versions central to Viking's strategy in a market projected to exceed $100 billion in annual sales [12]